AFFILIATIONS
1 Boston Children’s Hospital, Boston, Massachusetts, United States, Broad Institute, Cambridge, Massachusetts, United States, Dana-Farber Cancer Institute, Boston, Massachusetts, United States, Harvard Medical School, Boston, Massachusetts, United States, Harvard Stem Cell Institute, Cambridge, Massachusetts, United States
2 Boston Children’s Hospital, Boston, Massachusetts, United States, Broad Institute, Cambridge, Massachusetts, United States, Dana-Farber Cancer Institute, Boston, Massachusetts, United States, Harvard Medical School, Boston, Massachusetts, United States, Harvard Stem Cell Institute, Cambridge, Massachusetts, United States
3 Boston Children’s Hospital, Boston, Massachusetts, United States, Broad Institute, Cambridge, Massachusetts, United States, Dana-Farber Cancer Institute, Boston, Massachusetts, United States, Harvard Medical School, Boston, Massachusetts, United States, Harvard Stem Cell Institute, Cambridge, Massachusetts, United States, Massachusetts General Hospital Research Institute, Boston, Massachusetts, United States
4 Boston Children’s Hospital, Boston, Massachusetts, United States, Broad Institute, Cambridge, Massachusetts, United States, CHU de Québec–Université Laval Research Center, Québec, Quebec, Canada, Dana-Farber Cancer Institute, Boston, Massachusetts, United States, Harvard Medical School, Boston, Massachusetts, United States, Harvard Stem Cell Institute, Cambridge, Massachusetts, United States, Université Laval, Québec, Quebec, Canada
5 Boston Children’s Hospital, Boston, Massachusetts, United States, Broad Institute, Cambridge, Massachusetts, United States, Dana-Farber Cancer Institute, Boston, Massachusetts, United States, Harvard Medical School, Boston, Massachusetts, United States, Harvard Stem Cell Institute, Cambridge, Massachusetts, United States
ABSTRACT
Severe α0-thalassemia, caused by biallelic HBA1 and HBA2 (HBA1/2) gene deletions, leads to hemoglobin Bart’s hydrops fetalis syndrome (HBHFS), a lethal inherited blood disorder for which in utero or neonatal onset regular transfusions are required to sustain life and allogeneic hematopoietic stem cell transplantation remains the only potentially curative treatment. Restoration of α-globin expression represents a promising therapeutic strategy but remains technically challenging because conventional genome-editing approaches have limited capacity for targeted integration of large DNA fragments in hematopoietic stem cells. To address this challenge, we leveraged Prime Assembly (PA), a prime editing-based platform we recently developed that enables precise large-fragment genomic integration without introducing double-strand DNA breaks and is compatible with both double-stranded and single-stranded DNA donors. Here, we evaluated whether PA-mediated targeted integration of a functional HBA2 transcriptional unit could restore α-globin expression in α-thalassemia, examining how genomic integration site and endogenous enhancer activity influence transgene expression and neighboring gene regulation.
We generated K562 α0-thalassemia cells carrying the most common HBA1/2 deletion (the ~20.5 kb Southeast Asian or SEA deletion) in homozygosity. We used PA to integrate an HBA2 expression cassette linked to an EGFP reporter through a P2A peptide at multiple sites within and around the α-globin locus along with AAVS1 targeting as an ectopic control. PA-mediated integration yielded up to approximately 42.3% EGFP-positive cells in the presence of DNA repair inhibitors and up to 22.2% without inhibitor treatment. Comparison across integration sites revealed marked site-dependent differences in HBA2 expression. Integration at positions farther from the α-globin enhancers showed reduced HBA2 expression, whereas targeting the same cassette to the AAVS1 locus yielded negligible expression. Among the tested sites, sequences adjacent to the R4 α-globin enhancer, a non-coding regulatory element, supported high level HBA2 expression and was selected as the preferred integration site because it avoided direct disruption of protein-coding genes and is outside the breakpoints of the α0-thalassemia deletions associated with HBHFS. Integration at R4 substantially restored HBA2 expression in α0-thalassemia cells, reaching approximately 35% of parental K562 levels. Expression of other globin genes, including HBZ, HBB, and HBG1/2, was not significantly altered. R4-targeted integration also did not significantly affect the expression of the examined neighboring genes, including RHBDF1, MPG, NPRL3, and LUC7L. Furthermore, deletion of a 622-bp core region of the R2 α-globin enhancer markedly reduced expression of the integrated HBA2 cassette, indicating that the integrated HBA2 remained dependent on endogenous α-globin regulatory elements that remain intact despite α0-thalassemia deletion.
Together, these findings demonstrate that Prime Assembly enables targeted integration of an HBA2 expression cassette into the endogenous α-globin regulatory domain, resulting in therapeutically relevant restoration of α-globin expression. Integration at the R4 enhancer supported robust HBA2 expression without disrupting protein-coding sequences or significantly altering the expression of the examined neighboring genes. This strategy provides a promising framework for developing genome-editing therapy for severe α-thalassemia. More broadly, this work showcases prime assembly as an approach to replace deficient genes for inherited disease restoring endogenous gene regulation
DISCLOSURES
Yanhua Dong: No relevant conflicts of interest to declare.